- Home
- Automated
- List of product information
- ILIADIN SPRAY 0.05% [SIN02674P]
ILIADIN SPRAY 0.05% [SIN02674P]
Active ingredients: ILIADIN SPRAY 0.05%
Last updated 26 October 2025
On this page
Product Info
ILIADIN SPRAY 0.05%
[SIN02674P]
Product information
Active Ingredient and Strength | OXYMETAZOLINE HCL - 0.5 MG |
Dosage Form | SPRAY |
Manufacturer and Country | DELPHARM BLADEL B.V. - NETHERLANDS |
Registration Number | SIN02674P |
Licence Holder | PROCTER & GAMBLE (SINGAPORE) PTE LTD |
Forensic Classification | GENERAL SALE LIST |
Anatomical Therapeutic Chemical (ATC) code | R01AA05 |
Indications
Acute cold, paranasal sinusitis, syringitis, otitis media.
Dosage, mode of administration
Iliadin 0.05% Decongestant Nasal Spray is intended for intranasal application. Unless otherwise prescribed, spray 1 puff of Iliadin 0.05% Decongestant Nasal Spray into each nostril 2–3 times daily.
Iliadin 0.05% Decongestant Nasal Spray may only be administered to adults and children of 6 years and older and should not be used in small children and infants.
Duration of treatment
Unless specifically prescribed by the doctor, Iliadin 0.05% Decongestant Nasal Spray should only be used for short periods of time (5 to 7 days). A treatment-free period of several days should precede any repeated use.
Permanent use of decongestant rhinological agents may attenuate their effect. The abuse of local rhinological agents may cause mucosal atrophy and reactive hyperaemia with rhinitis medicamentosa.
Longer use of oxymetazoline may cause damage to the mucosal epithelium with inhibition of ciliary activity. This may possibly result in irreversible damage to the mucosa with rhinitis sicca.
Long term use and overdosage must be avoided, especially in children. Medical supervision is indicated in patients with chronic rhinitis. Dosage higher than recommended may only be used under supervision.
Contraindications
Rhinitis sicca, hypersensitivity to the active ingredient or to any of the excipients, children below six years of age.
In the following cases this drug may only be used after carefully weighing the risk-to-benefit ratio:
Patients treated with monamine oxidase inhibitors (MAO-inhibitors) and other drugs potentially increasing blood pressure
Increased intraocular pressure, especially narrow-angle glaucoma
Severe cardiovascular diseases (e.g. coronary heart disease, hypertension)
Phaeochromocytoma
Metabolic disorders (e.g. hyperthyroidism, diabetes mellitus, porphyria).
Hyperplasia of the prostate
Because of the benzalkonium chloride which is contained as preservative Iliadin 0.05% Decongestant Nasal Spray must not be used in known hypersensitivity to this substance.